【摘要】 目的探究枸橼酸莫沙必利联合磷酸铝治疗胆汁反流性胃炎的临床效果。方法选取2017年1月14日～2018年1月20日我院收治的86例胆汁反流性胃炎患者作为研究对象,按照随机数字表法将其分为对照组(43例)与观察组(43例)。其中对照组患者给予PPI联合枸橼酸莫沙必利治疗,观察组患者给予PPI以及枸橼酸莫沙必利联合磷酸铝治疗。比较两组患者的临床治疗总有效率、临床症状积分(反酸、恶心、腹胀、烧心、上腹痛)及不良反应发生率(便秘、口干、腹泻)。结果观察组患者治疗后的临床总有效率为97.67%(42/43),高于对照组的72.09%(31/43),差异有统计学意义(P<0.05)。观察组患者治疗后的临床积分[反酸(0.56±0.12)分、恶心(0.33±0.12)分、腹胀(0.58±0.15)分、烧心(0.63±0.20)分、上腹痛(0.52±0.10)分)]均低于对照组[反酸(1.63±0.36)分、恶心(1.36±0.26)分、腹胀(1.65±0.40)分、烧心(2.36±0.78)分、上腹痛(1.98±0.52)分)],差异有统计学意义(P<0.05)。观察组患者治疗后的不良反应发生率为2.33%(1/43),低于对照组的18.60%(8/43),差异有统计学意义(P<0.05)。结论枸橼酸莫沙必利联合磷酸铝治疗胆汁反流性胃炎具有较高的临床价值,能够在缓解临床症状的基础上降低不良反应发生率,值得应用及推广。更多还原

【Abstract】 Objective To explore the clinical effect of Mosapride Citrate combined with Aluminum Phosphate in the treatment of bile reflux gastritis. Methods A total of 86 cases of bile reflux gastritis treated in our hospital from January 14, 2017 to January 20, 2018 were selected as the subjects and divided into the control group(43 cases) and the observation group(43 cases) according to the random number method. The control group was treated with PPI combined with Mosapride Citrate, and the observation group was given the PPI and Mosapride Citrate combined with Aluminum Phosphate. The clinical total effective rate and clinical symptom score(anti acid, nausea, abdominal distention, heartburn,upper abdominal pain) and the incidence of adverse reactions(constipation, dry mouth, diarrhea) were compared between the two groups. Results The total effective rate of the observation group after treatment was 97.67%(42/43), which was higher than that of the control group of 72.09%(31/43), and the difference was statistically significant(P<0.05). The clinical scores of the observation group(sour regurgitation of [0.56±0.12] points, nausea of [0.33±0.12] points, abdominal distension of [0.58±0.15] points, heartburn of [0.63±0.20] points and epigastric pain of [0.52±0.10] points) were lower than those in the control group(sour regurgitation of [1.63±0.36] points, nausea of [1.36±0.26] points, abdominal distention of [1.65±0.40] points, heartburn of [2.36±0.78] points and epigastric pain of [1.98±0.52] points), the differences were statistically significant(P<0.05). The incidence of adverse reactions after treatment in the observation group was2.33%(1/43), which was lower than that in the control group of 18.60%(8/43), and the difference was statistically significant(P<0.05). Conclusion The combination of Mosapride Citrate and Aluminum Phosphate is of high clinical value in the treatment of bile reflux gastritis. It can reduce the incidence of adverse reactions on the basis of relieving clinical symptoms. It is worth applying and popularizing.更多还原